Clinical and economic impact of a specialty care management program among patients with multiple sclerosis: A cohort study

Multiple Sclerosis

Volumn 16, Issue 8, 2010, Pages 956-963

  Tan, H ^a   Yu, J ^a   Tabby, D ^b   Devries, A ^a   Singer, J ^a  

^a HEALTHCORE INC   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

care management; cohort study; healthcare costs; hospitalization rate; medication adherence and persistence; multiple sclerosis; specialty pharmacy

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE; NATALIZUMAB;

ADULT; ARTICLE; COHORT ANALYSIS; COMORBIDITY; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH ECONOMICS; HEALTH MAINTENANCE ORGANIZATION; HOSPITALIZATION; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PATIENT COMPLIANCE; PHARMACY; PREFERRED PROVIDER ORGANIZATION; RETROSPECTIVE STUDY;

ADULT; COHORT STUDIES; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; MALE; MANAGED CARE PROGRAMS; MEDICATION ADHERENCE; MIDDLE AGED; MULTIPLE SCLEROSIS; PHARMACEUTICAL SERVICES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED STATES;

EID: 77955169179     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458510373487     Document Type: Article

References (25)

1. Noonan CW, Kathman SJ and White MC Prevalence estimates for MS in the United States and evidence of an increasing trend for women. Neurology 2002 ; 58: 136-138.
2. Anderson DW, Ellenberg JH, Leventhal CM, Reingold SC, Rodriguez M. and Silberberg DH Revised estimate of the prevalence of multiple sclerosis in the United States. Ann Neurol 1992 ; 31: 333-336.
3. Who gets MS? Available at: http://www.nationalmssociety.org/about- multiple-sclerosis/who-gets-ms/index.aspx. National Multiple Sclerosis Society. ( 2008, accessed August 2009 ).
4. Noseworthy JH, Lucchinetti C., Rodriguez M. and Weinshenker BG Multiple sclerosis. N Engl J Med 2000 ; 343: 938-952.
5. Courtney AM, Treadaway K., Remington G. and Frohman E. Multiple sclerosis. Med Clin North Am 2009 ; 93: 451-476.
6. Goodin DS, Frohman EM, Garmany Jr. GP, et al. Disease-modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002 ; 58: 169-178.
7. Goodin DS Disease-modifying therapy in multiple sclerosis: update and clinical implications. Neurology 2008 ; 71: S8-13.
8. Cloutier MM, Grosse SD, Wakefield DB, Nurmagambetov TA and Brown CM The economic impact of an urban asthma management program. Am J Manag Care 2009 ; 15: 345-351.
9. Holtz-Eakin D. An analysis of the literature on disease management programs. Available at: http://www.cbo.gov/ftpdocs/59xx/doc5909/10-13- DiseaseMngmnt.pdf. Congressional Budget Office. ( 2004, accessed August 2009 ).
10. McAlister FA, Lawson FM, Teo KK and Armstrong PW Randomised trials of secondary prevention programmes in coronary heart disease: systematic review. BMJ 2001 ; 323: 957-962.
11. Riegel B., Carlson B., Kopp Z., LePetri B., Glaser D. and Unger A. Effect of a standardized nurse case-management telephone intervention on resource use in patients with chronic heart failure. Arch Intern Med 2002 ; 162: 705-712.
12. Taylor CB, Miller NH, Reilly KR, et al. Evaluation of a nurse-care management system to improve outcomes in patients with complicated diabetes. Diabetes Care 2003 ; 26: 1058-1063.
13. Kopke S., Kasper J., Muhlhauser I., Nubling M. and Heesen C. Patient education program to enhance decision autonomy in multiple sclerosis relapse management: a randomized-controlled trial. Mult Scler 2009 ; 15: 96-104.
14. Navipour H., Madani H., Mohebbi MR, Navipour R., Roozbayani P. and Paydar A. Improved fatigue in individuals with multiple sclerosis after participating in a short-term self-care programme. NeuroRehabilitation 2006 ; 21: 37-41.
15. Forbes A., While A., Mathes L. and Griffiths P. Evaluation of a MS specialist nurse programme. Int J Nurs Stud 2006 ; 43: 985-1000.
16. Sauter C., Zebenholzer K., Hisakawa J., Zeitlhofer J. and Vass K. A longitudinal study on effects of a six-week course for energy conservation for multiple sclerosis patients. Mult Scler 2008 ; 14: 500-505.
17. Patten SB, Newman S., Becker M., Riddell C. and Metz L. Disease management for depression in an MS clinic. Int J Psychiatry Med 2007 ; 37: 459-473.
18. Andrade SE, Kahler KH, Frech F. and Chan KA Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006 ; 15: 565-574.
19. Cramer JA, Roy A., Burrell A., et al. Medication compliance and persistence: terminology and definitions. Value Health 2008 ; 11: 44-47.
20. Osterberg L. and Blaschke T. Adherence to medication. N Engl J Med 2005 ; 353: 487-497.
21. Prescott JD, Factor S., Pill M. and Levi GW Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. J Manag Care Pharm 2007 ; 13: 44-52.
22. Russo P., Capone A., Paolillo A., et al. Cost-analysis of relapsing-remitting multiple sclerosis in Italy after the introduction of new disease-modifying agents. Clin Drug Investig 2004 ; 24: 409-420.
23. Bunn III WB, Baver RS, Ehni TK, et al. Impact of a musculoskeletal disability management program on medical costs and productivity in a large manufacturing company. Am J Manag Care 2006 ; 12 (Spec no): SP27 - SP32.
24. Ofman JJ, Badamgarav E., Henning JM, et al. Does disease management improve clinical and economic outcomes in patients with chronic diseases? A systematic review. Am J Med 2004 ; 117: 182-192. (Pubitemid 39055870)
25. Ose D., Wensing M., Szecsenyi J., Joos S., Hermann K. and Miksch A. Impact of primary care-based disease management on the health-related quality of life in patients with type 2 diabetes and co-morbidity. Diabetes Care 2009 ; 32: 1594-1596.